13 Apr Reset T1D
TrialNet is studying rezpegaldesleukin to see if it can help the body continue making insulin in people newly diagnosed with type 1 diabetes (TID) by stimulating regulatory T cells to restore immune balance.
Rezpegaldesleukin is already being studied in people with other autoimmune diseases like psoriasis and eczema. This is the first time it is being studied in people with TID.
Like all clinical research, there are benefits and risks to participating in this study. Before you join the study, a TrialNet team member will explain all potential benefits and risks and answer your questions.
Participant Eligibility
-Newly diagnosed with T1D (in the past 3 months)
-Ages 18 to 45
Your screening tests show:
-1 or more diabetes-related autoantibody
-Detectable C-peptide during a mixed meal tolerance test (MMTT)
A research team member will go over the full list of eligibility criteria with you before your screening visit.
Contact
the Outreach Team
(800) 888-4187
Additional Study Details
Full Study Title
Rezpegaldesleukin for Newly Diagnosed T1D Study (RESET T1D)
Investigator(s)
Kurt Griffin, MD
Accepts Healthy Volunteers?
No
Study Site(s)
Benaroya Research Institute
1201 9th Ave
Seattle, Washington 98101
